Nektar to Announce Financial Results for the Second Quarter on Thursday, August 7, 2025, After Close of U.S.-Based Financial Markets

Company Overview - Nektar Therapeutics is a clinical-stage biotechnology company focused on developing treatments for autoimmune and chronic inflammatory diseases [3] - The company's lead product candidate is rezpegaldesleukin (REZPEG, or NKTR-358), a first-in-class regulatory T cell stimulator currently in two Phase 2b clinical trials for atopic dermatitis and alopecia areata [3] - Nektar's pipeline includes a preclinical bivalent tumor necrosis factor receptor type II (TNFR2) antibody, bispecific programs NKTR-0165 and NKTR-0166, and a modified hematopoietic colony stimulating factor (CSF) protein, NKTR-422 [3] - The company is also evaluating NKTR-255, an investigational IL-15 receptor agonist aimed at enhancing the immune system's ability to combat cancer, in several ongoing clinical trials [3] Upcoming Financial Results - Nektar Therapeutics will announce its financial results for the second quarter on August 7, 2025, after the close of U.S. financial markets [1] - Howard Robin, President and CEO, will host a conference call to review the results starting at 5:00 p.m. Eastern Time [1] Access to Conference Call - The press release and live audio-only webcast of the conference call can be accessed through a link on Nektar's website [2] - The web broadcast will be available for replay until September 7, 2025 [2] - Participants can pre-register for the conference call to receive dial-in information and a PIN [2]